But narrowing down the exact genes responsible proves to be complicated… While people of Mexican ancestry are nearly twice as likely to develop type 2 diabetes as people of European heritage, the majority of research in this area has focused on those of European origin. In an effort to understand …
Read More »Glargine vs. Liraglutide in Poorly Controlled Type 2 Diabetes Treatment
Both medications lowered HbA1c and both groups of patients lost weight…. This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5–12%. Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0–5.5 mmol/L or liraglutide, escalated …
Read More »Linagliptin/Metformin Combination vs Linagliptin Monotherapy for Type 2 Diabetes
Earlier treatment for poorly controlled type 2 diabetes patients is advocated… Researchers from the University of Calgary, Alberta, Canada, evaluated glucose-lowering treatment strategies with linagliptin and metformin in people with newly diagnosed type 2 diabetes and marked hyperglycemia, a prevalent population for which few dedicated studies of oral antidiabetes drugs …
Read More »New Guideline Released on Pharmacological Management of Obesity
The Endocrine Society has released a clinical practice guideline on the pharmacological management of obesity that includes recommendations on strategies for prescribing weight loss drugs.
Read More »Tattoo-Based Sensor Detects Glucose Levels
An ultra-thin, flexible sensor that sticks to the skin like a temporary tattoo can detect a person’s blood glucose levels… “The sensor represents the first example of an easy-to-wear flexible tattoo-based epidermal diagnostic device combining reverse iontophoretic extraction of interstitial glucose and an enzyme-based amperometric biosensor,” the researchers wrote. In …
Read More »FDA Approves Maestro Electronic Weight Loss Device
The FDA has approved the Maestro Rechargeable System for treatment of obesity… The Maestro Rechargeable System is indicated for treatment of patients aged at least 18 years with a BMI of 35 to 45 with at least one obesity-related condition and who have failed to lose weight on a weight …
Read More »Acarbose Higher Cardiovascular Risk Than Metformin
According to a new retrospective study acarbose may not have a cardioprotective effect as good as metformin when used as first-line therapy… This study analyzed 17,366 patients who initiated acarbose therapy and 230,023 who initiated metformin therapy. Both nephropathy and diabetes complication severity index were strongly associated with the patients …
Read More »Exercise Makes People Live Young
In the study, the older athletes’ physical functions were more similar to that of young adults than of people their age… In a cross-sectional cohort study, researchers measured the relationship between age and physiological activity in healthy older individuals. The study included 84 male and 41 female cyclists aged 55 …
Read More »Higher Fasting Blood Glucose Linked with Risk of Pancreatic Cancer
For every 0.56 mmol/L increase in fasting blood glucose there was a 14% increase in the rate of pancreatic cancer… In previous studies, an assumption has been made that diabetes may be either a risk factor or a symptom of pancreatic cancer. To investigate this connection, researchers examined both linear …
Read More »Lower Mood and its Association with Risk Factors of Type 2 Diabetes
Low mood in healthy children is associated with poorer metabolic health independently of adiposity… Mood comprises two main traits – positive and negative affect, both associated with depression and anxiety. Studies in children have linked depression with obesity, but the association with metabolic health is unclear. Researchers from Plymouth University …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.